Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback